• C Koenecke, B Hertenstein, J Schetelig, A van Biezen, E Dammann, A Gratwohl, A Ganser, M Schleuning, M Bornhäuser, N Jacobsen, N Kröger, D Niederwieser, T de Witte, and T Ruutu.
• Hannover Medical School, Department of Hematology, Hemostasis, Hannover, Germany. koenecke.christian@mh-hannover.de
• Am. J. Transplant. 2010 Aug 1; 10 (8): 1897-906.

AbstractTo analyze the outcome of solid organ transplantation (SOT) in patients who had undergone allogeneic hematopoietic stem cell transplantation (HSCT), a questionnaire survey was carried out within 107 European Group of Blood and Marrow Transplantation centers. This study covered HSCT between 1984 and 2007 in Europe. Forty-five SOT in 40 patients were reported. Fifteen liver, 15 renal, 13 lung, 1 heart and 1 skin transplantations were performed in 28 centers. Overall survival (OS) of patients after SOT was 78% at 5 years (95% confidence interval [CI], 64% to 92%). OS at 5 years was 100% for renal, 71% (95% CI, 46% to 96%) for liver and 63% (95% CI, 23% to 100%) for lung transplant recipients. The 2-year-incidence of SOT failure was 20% (95% CI, 4% to 36%) in patients with graft-versus-host disease (GvHD) and 7% (95% CI, 0% to 21%) in patients without GvHD before SOT. The relapse incidence for underlying malignant diseases was 4% at 5 years (95% CI, 0% to 12%). In summary, this study shows that selected patients receiving SOT after HSCT have a remarkably good overall and organ survival. These data indicate that SOT should be considered in selected patients with single organ failure after HSCT.

21 keywords...

hide…